Minnesota 2025-2026 Regular Session

Minnesota House Bill HF3054

Introduced
4/2/25  

Caption

Prescription drug transparency provisions modified.

Impact

The proposed changes underpin a broader initiative to regulate and oversee prescription drug pricing transparency in Minnesota. By establishing rigorous reporting obligations for covered entities, HF3054 aims to simplify the tracking of drug costs and enhance public awareness regarding the financial aspects tied to prescription medications. The shift could potentially empower consumers and regulatory bodies to better understand market dynamics and facilitate more informed legislative action aimed at curbing excessive pricing practices among pharmaceutical companies.

Summary

House File 3054 seeks to enhance transparency in prescription drug pricing by modifying existing provisions related to the reporting of costs and revenues for entities participating in the federal 340B program. The bill proposes amendments to Minnesota Statutes aiming to require covered entities, such as hospitals and pharmacies, to report specific data regarding drug acquisition costs, payments received, pricing units, and any associated payments made to contract pharmacies. This reporting requirement encompasses both the forms of payment and the payer types which include commercial insurance, Medicaid, and Medicare, creating a comprehensive data landscape regarding drug pricing and accessibility for stakeholders.

Contention

While HF3054 is aimed at accountability and transparency, its implementation may invite contention among stakeholders. For instance, pharmaceutical manufacturers may argue that the increased reporting requirements could burden their operations and hinder competitive practices. Conversely, advocates for drug pricing reform contend that transparency is crucial for enabling fair market competition and ensuring accessible medication for consumers. As such, the discussions around the bill indicate a duality in perspectives regarding the balance between industry operational freedom and consumer rights.

Companion Bills

MN SF3294

Similar To Prescription drug transparency provisions modifications

Previously Filed As

MN SF3294

Prescription drug transparency provisions modifications

MN SF2477

Health insurance, Medicare supplement benefits and prescription drugs provisions modifications

MN SB1340

Modifies provisions relating to payments for prescription drugs, including 340B drugs

MN SF4419

Various prescription drug transaction, coverage, and data provisions modifications

MN SB372

Enacts provisions relating to payments for prescription drugs

MN S875

To promote transparency in prescription drug prices

MN SB45

Enacts provisions relating to payments for prescription drugs

MN SB512

Enacts provisions relating to payments for prescription drugs

MN HB1012

Prescription Drug Benefit Information Transparency

MN HB3794

PRESCRIPTION DRUGS-VARIOUS

Similar Bills

CA AB2570

Elderly Parole Program.

MN HF1994

Payment rates established for certain substance use disorder treatment services, and vendor eligibility recodified for payments from the behavioral health fund.

MN SF1826

Payment rates establishment for certain substance use disorder treatment services

TX HB1080

Relating to the publication of required notice by a political subdivision by alternative media.

CA SB680

Sex offender registration: unlawful sexual intercourse with a minor.

CA AB387

An act to amend Section 219 of the Code of Civil Procedure, relating to juries.

MN HF618

Exemption provisions modified for construction materials by contractors, and refund provision added.

MN SF1724

Exemption provisions modification for construction materials by certain contractors